Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2015

01-06-2015 | Research Article

MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition

Authors: Xiaolin Liu, Ruifen Dong, Zhijun Jiang, Yuyan Wei, Yingwei Li, Linxuan Wei, Hengzi Sun, Yinuo Li, Ning Yang, Qifeng Yang, Zhaojian Liu, Beihua Kong

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

Ovarian cancer is a highly invasive cancer with poor prognosis. Previous studies have revealed lots of connections between the invasiveness and epithelial-mesenchymal transition (EMT), which is common during the progression of ovarian cancer. MDC1, a mediator of DNA damage checkpoint, has recently been implicated as a potential oncogene. Here, in this article, we studied the role of MDC1 in ovarian cancer metastasis. First, in tissue samples, we found that high expression level of MDC1 was correlated with poor prognosis. Furthermore, MDC1 overexpression in ovarian cancer cells significantly increased migration and invasion. In contrast, silencing MDC1 reversed these processes. Consistently, nude mice xenograft confirmed that silencing MDC1 suppressed tumor metastasis in vivo. We further demonstrated that MDC1 induced EMT through modulation EMT markers such as E-cadherin, N-cadherin, and vimentin. Taken together, our findings suggest that MDC1 promotes ovarian cancer metastasis through the induction of EMT.
Appendix
Available only for authorised users
Literature
1.
2.
Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.CrossRef
3.
De Craene B, Berx G. Regulatory networks defining emt during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.CrossRefPubMed
4.
Kim MK, Kim MA, Kim H, Kim YB, Song YS. Expression profiles of epithelial-mesenchymal transition-associated proteins in epithelial ovarian carcinoma. BioMed Res Int. 2014;2014:495754.PubMedPubMedCentral
5.
Huang RY, Chung VY, Thiery JP. Targeting pathways contributing to epithelial-mesenchymal transition (emt) in epithelial ovarian cancer. Curr Drug Targets. 2012;13:1649–53.CrossRefPubMed
6.
Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291:59–66.CrossRefPubMed
7.
Stucki M, Jackson SP. Mdc1/nfbd1: A key regulator of the DNA damage response in higher eukaryotes. DNA Repair. 2004;3:953–7.CrossRefPubMed
8.
Coster G, Goldberg M. The cellular response to DNA damage: A focus on mdc1 and its interacting proteins. Nucleus. 2010;1:166–78.CrossRefPubMed
9.
10.
Lou Z, Minter-Dykhouse K, Franco S, Gostissa M, Rivera MA, Celeste A, et al. Mdc1 maintains genomic stability by participating in the amplification of atm-dependent DNA damage signals. Mol Cell. 2006;21:187–200.CrossRefPubMed
11.
Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ. Mdc1 is a mediator of the mammalian DNA damage checkpoint. Nature. 2003;421:961–6.CrossRefPubMed
12.
Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP. Mdc1 directly binds phosphorylated histone h2ax to regulate cellular responses to DNA double-strand breaks. Cell. 2005;123:1213–26.CrossRefPubMed
13.
d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194–8.CrossRefPubMed
14.
Goldberg M, Stucki M, Falck J, D’Amours D, Rahman D, Pappin D, et al. Mdc1 is required for the intra-s-phase DNA damage checkpoint. Nature. 2003;421:952–6.CrossRefPubMed
15.
Lou Z, Minter-Dykhouse K, Wu X, Chen J. Mdc1 is coupled to activated chk2 in mammalian DNA damage response pathways. Nature. 2003;421:957–61.CrossRefPubMed
16.
Nakanishi M, Ozaki T, Yamamoto H, Hanamoto T, Kikuchi H, Furuya K, et al. Nfbd1/mdc1 associates with p53 and regulates its function at the crossroad between cell survival and death in response to DNA damage. J Biol Chem. 2007;282:22993–3004.CrossRefPubMed
17.
Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12:587–98.CrossRefPubMed
18.
Watanabe S, Watanabe K, Akimov V, Bartkova J, Blagoev B, Lukas J, et al. Jmjd1c demethylates mdc1 to regulate the rnf8 and brca1-mediated chromatin response to DNA breaks. Nat Struct Mol Biol. 2013;20:1425–33.CrossRefPubMed
19.
Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, et al. Poly (adp-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J Biol Chem. 2014;289:20543–58.CrossRefPubMedPubMedCentral
20.
Yang Z, Bu Y, Wang C, Liu G, Song F. Growth inhibition, morphology change, and cell cycle alterations in nfbd1-depleted human esophageal cancer cells. Mol Cell Biochem. 2010;342:1–6.CrossRefPubMed
21.
Yuan C, Bu Y, Wang C, Yi F, Yang Z, Huang X, et al. Nfbd1/mdc1 is a protein of oncogenic potential in human cervical cancer. Mol Cell Biochem. 2012;359:333–46.CrossRefPubMed
22.
Ye Q, Chen L, Yin X, Liu YJ, Ji Q, Zhao E: Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins. Pathology oncology research. POR. 2014.
23.
Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One. 2009;4:e6529.CrossRefPubMedPubMedCentral
24.
Welcsh PL, King MC. Brca1 and brca2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:705–13.CrossRefPubMed
25.
26.
Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12:801–17.CrossRefPubMed
27.
Goodwin JF, Knudsen KE: Beyond DNA repair: DNA-pk function in cancer. Cancer discovery. 2014.
28.
29.
Masutani M, Fujimori H. Poly (adp-ribosyl) ation in carcinogenesis. Mol Aspects Med. 2013;34:1202–16.CrossRefPubMed
30.
31.
Bartkova J, Horejsi Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, et al. DNA damage response mediators mdc1 and 53 bp1: Constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene. 2007;26:7414–22.CrossRefPubMed
32.
Wang B, Zhang L, Qiu F, Fang W, Deng J, Zhou Y, et al. A newfound association between mdc1 functional polymorphism and lung cancer risk in chinese. PLoS One. 2014;9:e106794.CrossRefPubMedPubMedCentral
Metadata
Title
MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition
Authors
Xiaolin Liu
Ruifen Dong
Zhijun Jiang
Yuyan Wei
Yingwei Li
Linxuan Wei
Hengzi Sun
Yinuo Li
Ning Yang
Qifeng Yang
Zhaojian Liu
Beihua Kong
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3063-5

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue

Research Article

Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients

Review

Isothiocyanates: a class of bioactive metabolites with chemopreventive potential

Research Article

Downregulation of Id2 increases chemosensitivity of glioma

Research Article

Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity

Research Article

Interferon gamma +874 T/A polymorphism increases the risk of cervical cancer: evidence from a meta-analysis

Review

New approaches for cancer immunotherapy

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits